SIGFOX
An Post, the leading mails, parcels and ecommerce logistics company in Ireland, has contracted VT-IoT, the operator of Ireland’s Sigfox 0G network to revolutionise their supply chain with IoT tracking devices as part of their innovative and fast-moving digital transformation strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200228005183/en/
As masters of delivery, An Post Mails & Parcels is rapidly changing from the old world of traditional letters to the new world of ecommerce parcel logistics and B2B services for Irish and international businesses. An Post runs Ireland’s largest fleet, including the country’s largest fleet of electric vehicles. It recently opened its new fully automated Dublin Parcel Hub and its operational infrastructure includes a large volume of returnable transport units such as roll cages and containers.
To provide an efficient and cost-effective service, An Post require a systematically integrated operational process. The roll cages and containers in which parcels are transported must be available every day in the required quantities in the Company’s mails hubs across the country.
With the advance of revolutionary Internet of Things (IoT) technology, VT and Sigfox are providing An Post with the solution they need to optimise their supply chain. Smart tracking devices empower An Post to monitor the location of their assets nationwide, even outside their own supply chain. Using Sigfox, the world’s leading IoT service provider and first global 0G network operator, has eliminated the barriers associated with traditional tracking technologies: price, battery life and coverage, by providing low cost, low power connectivity over a single global network today available in more than 70 countries.
“VT’s state-of-the-art solution has resulted in significantly increased transparency in our postal distribution network, ensuring world class quality of service for our customers and lower operational costs through improved containerisation efficiency”, explains Mark Devine, National Engineering Maintenance & Performance Manager, An Post .
“Our collaboration with An Post is an exciting step forward into the future of industrial IoT and a key milestone toward connecting billions of IoT devices globally on the Sigfox 0G network. We are confident our solutions have the power to truly revolutionise the way logistics and supply chain companies do business, resulting in significantly reduced costs and increased efficiencies .” Mark Bannon, CEO, VT.
““We are delighted to support An Post in this new era of industry 4.0, where we are making the once untraceable now entirely visible to organisations. We continue to deliver benefits to Postal organisations, like An Post in Ireland, DHL in Germany and Posti in Finland. This is a key vertical for Sigfox, where we strive to deliver value and thought leadership in Global Supply Chain & Logistics." Glen Robinson, SVP Global Sales & Marketing, Sigfox.
About An Post
An Post provides world-class mails, e-commerce parcels, financial and communications services to national and international business. It delivers two million items of mail to 2.2 million address points nationwide every working day, as well as evening and weekend parcels deliveries.
About VT
VT is a 0G IoT network operator and a pioneer of IoT solutions within the Supply Chain and Aerospace markets. Our purpose is to empower our enterprise users to transform their business models and operations through our leading-edge device to cloud 0G solutions. Our nationwide Sigfox IoT telecoms network currently delivers over 95% geographical coverage to Ireland – we are passionate about enabling every person, home and business to benefit from 0G IoT.
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox’s unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 70 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200228005183/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
